CP-690550
CP-690550 | Unit size | Cat. code | Docs | Price |
---|---|---|---|---|
JAK3 Inhibitor |
5 mg |
tlrl-cp69 |
JAK3 Inhibitor
CP-690550 (Tofacitinib) specifically inhibits JAK3, which has a pivotal role in cytokine signal transduction that governs lymphocyte survival, proliferation, differentiation, and apoptosis [1].
In experimental models, treatment with CP-690550 decreases IL-6 production, a critical cytokine that drives inflammation [2]. Moreover, it has been shown that CP-690550 also inhibits TNF-induced chemokine expression [3].
References:
1. Wu W. & Sun X., 2012. Janus kinase 3: the controller and the controlled. Acta Biochim Biophys Sin. 44(3):187-96.
2. Milici A. et al., 2008. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther. 10: R14.
3. Sanna Rosengren S. et al., 2012. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I IFN. Ann Rheum Dis 71:440-7.
Specifications
Synonym: Tofacitinib
CAS number: 477600-75-2
Formula: C16H20N6O
Molecular weight: 312.37
Solubility: 100 mg/ml in DMSO
Purity: ≥96% (HPLC)
Working concentration: 50 nM - 1 µM
Quality control: The absence of bacterial contamination (e.g. lipoproteins and endotoxins) is confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the topContents
CP-690550 is provided as a solid.
- 5 mg CP-690550
CP-690550 is shipped at room temperature.
Store at -20°C.
Solid product is stable for 2 years when properly stored.